Hold-rated reports

933 tickers rated Hold
Ranks this page's recent reports by score.
Columbia Financial, Inc.
CLBK·Financials
B ★★★Hold
Current$11.04
Target$12.14
Return+10.0%
Nov 2, 2026

Columbia Financial's expanded capital base and improving lending margins create an earnings recovery opportunity, but acquisition integration risks and currently inadequate returns on equity limit its near-term investment appeal.

Score
66
Trinity Industries, Inc.
TRN·Industrials
B ★★★Hold
Current$30.99
Target$31.85
Return+2.8%
Nov 2, 2026

Trinity Industries offers cyclical railcar recovery potential, high fleet utilization, and dividend income, but substantial financing leverage and transaction-sensitive earnings limit near-term investment conviction.

Score
69
Hamilton Insurance Group, Ltd.
HG·Financials
B ★★★Hold
Current$35.06
Target$40.23
Return+14.7%
Nov 2, 2026

Hamilton combines profitable specialty underwriting, strong capital returns, and differentiated investment capabilities, but catastrophe losses, volatile investment earnings, and a higher historical valuation multiple constrain near-term upside.

Score
73
Miami International Holdings, Inc.
MIAX·Financials
B ★★★Hold
Current$34.67
Target$42.00
Return+21.1%
Nov 2, 2026

Miami International Holdings offers scalable exchange infrastructure, rising options profitability, and substantial liquidity, but concentrated trading-volume exposure, competitive pricing, and unproven futures investments constrain the margin of safety.

Score
74
CNO Financial Group, Inc.
CNO·Financials
B ★★★Hold
Current$58.04
Target$62.40
Return+7.5%
Nov 2, 2026

CNO offers durable middle-income insurance demand, improving normalized returns, and meaningful buybacks, but its elevated historical valuation and exposure to actuarial and investment risks limit near-term upside.

Score
68
Ryan Specialty Holdings, Inc.
RYAN·Financials
B ★★★Hold
Current$43.84
Target$48.00
Return+9.5%
Nov 2, 2026

Ryan Specialty's specialized insurance distribution network and growing underwriting management operations support long-term earnings growth, but slowing organic revenue, leverage, and compensation pressure limit near-term upside.

Score
67
Insmed Incorporated
INSM·Healthcare
B ★★★Hold
Current$110.31
Target$133.87
Return+21.4%
Nov 2, 2026

Insmed's rapidly expanding BRINSUPRI franchise and late-stage respiratory pipeline offer substantial long-term growth, but negative cash flow, shareholder dilution, and demanding commercialization expectations constrain near-term risk-adjusted returns.

Score
69
ATI Inc.
ATI·Industrials
B ★★★Hold
Current$177.92
Target$195.00
Return+9.6%
Nov 2, 2026

ATI benefits from durable aerospace qualification barriers, rising specialty-alloy demand, and expanding margins, but elevated valuation and capital-intensive manufacturing limit its margin of safety.

Score
67
The RealReal, Inc.
REAL·Consumer Discretionary
B ★★★Hold
Current$12.76
Target$14.63
Return+14.7%
Nov 2, 2026

The RealReal combines accelerating luxury resale adoption with improving marketplace profitability, but elevated earnings multiples, uneven free cash flow, and potential dilution limit its current margin of safety.

Score
68
Healthcare Realty Trust Incorporated
HR·Real Estate
B ★★★Hold
Current$18.49
Target$20.64
Return+11.6%
Nov 2, 2026

Healthcare Realty offers attractive REIT income and improving medical outpatient property cash flows, but elevated leverage and portfolio restructuring limit the certainty of sustained per-share earnings growth.

Score
74
Eastman Chemical Company
EMN·Materials
B ★★★Hold
Current$66.53
Target$76.80
Return+15.4%
Nov 2, 2026

Eastman's discounted specialty-materials portfolio and circular-recycling growth opportunity offer recovery potential, but elevated leverage, uneven cash conversion, and cyclical industrial demand constrain the near-term investment case.

Score
74
Norwegian Cruise Line Holdings Ltd.
NCLH·Consumer Discretionary
B ★★★Hold
Current$18.16
Target$20.40
Return+12.3%
Nov 2, 2026

Norwegian Cruise Line offers turnaround upside through improving yields, cost savings, and historically modest valuation multiples, but elevated leverage and negative free cash flow constrain the investment case.

Score
65